Biogen Inc vs LTC Properties Inc — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while LTC Properties Inc trades at $38.12 (market cap $2.05B). The key difference: Biogen Inc is far larger — about 14.7× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.98% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | LTC | |
|---|---|---|
Market Cap | $30.13B | $2.05B |
Sector | Health | Real Estate |
52-Week High | $216.63 | $42.81 |
52-Week Low | $128.93 | $33.98 |
Enterprise Value | $37.20B | $2.79B |
Dividend Yield | — | 5.98% |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →